| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:Eliglustat-d15 tartrate
CAS:1884556-84-6
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Eliglustat-d15 (tartrate)
CAS:1884556-84-6
Purity:>95% Package:1mg;5mg
|
| Company Name: |
Cayman Chemical Company
|
| Tel: |
(800) 364-9897 |
| Email: |
cayman@caymanchem.com |
| Products Intro: |
Product Name:Eliglustat-d15 (tartrate)
CAS:1884556-84-6
|
|
| | Eliglustat-d15 Tartrate Basic information |
| Product Name: | Eliglustat-d15 Tartrate | | Synonyms: | Eliglustat-d15 Tartrate;N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide-2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-d15, (2R,3R)-2,3-dihydroxybutanedioate | | CAS: | 1884556-84-6 | | MF: | C27H42N2O10 | | MW: | 554.64 | | EINECS: | | | Product Categories: | | | Mol File: | 1884556-84-6.mol |  |
| | Eliglustat-d15 Tartrate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: soluble,Methanol: soluble, | | form | A solid | | Water Solubility | Water: soluble |
| | Eliglustat-d15 Tartrate Usage And Synthesis |
| Biological Activity | Eliglustat-d15 is intended for use as an internal standard for the quantification of eliglustat by GC- or LC-MS. Eliglustat is an inhibitor of glucosylceramide synthase (IC50 = 40 nM for inhibition of glucosylceramide production in K562 cells).1 It is selective for glucosylceramide synthase over α-glucosidase I and II, α-1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase (IC50s = >10 μM for all). It decreases cell surface levels of the gangliosides GM1 and GM3 in K562 and B16/F10 cells with IC50 values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease. | | References | 1.McEachern, K.A., Fung, J., Komarnitsky, S., et al.A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseMol. Genet. Metab.91(3)259-267(2007) |
| | Eliglustat-d15 Tartrate Preparation Products And Raw materials |
|